Replies to post #45552 on Biotech Values

[DewDiligence]

>Based on the press release, my understanding was that the ALNY's drug contains two separate RNAi nucleotides-one targeting VEGF and the other targeting KSP (two separate active ingredients). Consequently, I was surprised that they were not running mono trials first.<

Sirna (now part of Merck) is doing the same thing in HCV. They linked two siRNAs with a carrier in order to attack two different vulnerabilities in the HCV replication cascade. But it’s considered one active ingredient because it starts out as one covalently bonded molecule.